A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer

Jung-Sun KIM; Koung-Jin SUH; Dae-Won LEE; Go-un WOO; Miso KIM; Se-Hyun KIM; Han-Suk RYU; Kyung-Hun LEE; Tae-Yong KIM; Sae-Won HAN; So-Yeon PARK; In-Ae PARK; Jee-Hyun KIM; Seock-Ah IM.
Cancer Research and Treatment ; : 488-496, 2022.
Artículo en Inglés | WPRIM | ID: wpr-925669

Documentos relacionados

  1. A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer.
  2. Obstetric and neonatal outcomes following taxane use during pregnancy: a systematic review.
  3. Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience.
  4. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
  5. Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.
  6. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
  7. First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
  8. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
  9. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
  10. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.